Evidence map›Paper›PMID 40461678›Full record

ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025

Sustained response to trametinib in an adult patient with neurofibromatosis type 1 and high-grade glioma.

Bertrand Dion, Sayanthen Sathyakumar, Jacob Silverman, Hallie Coltin, Geneviève Legault, Sébastien Perreault, Myreille D'Astous, Nathalie Lessard, Stephan Saikali, Norbert Dion and 4 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Bertrand Dion *Faculty of Medicine, Université Laval, Québec, Canada.
Sayanthen Sathyakumar *University of Toronto, Toronto, ON, Canada.
Jacob SilvermanMcGill Faculty of Medicine and Health Science, Montreal, Québec, Canada.
Hallie ColtinDivision of Hematology-Oncology, CHU Sainte Justine, Université de Montréal, Montréal, Québec, Canada.
Geneviève LegaultDepartment of Pediatrics, Division of Neurology, Montreal Children's Hospital-McGill University Health Center, Montreal, Québec, Canada.
Sébastien PerreaultDepartment of Pediatrics, Université de Montréal, Montreal, Québec, Canada.
Myreille D'AstousService de Neurochirurgie du Département de Chirurgie, CHU de Québec-Université Laval, Quebec City, Québec, Canada.
Nathalie LessardDepartment of Radio-oncology, CHU de Québec-Université Laval, Quebec City, Québec, Canada.
Stephan SaikaliDivision of Molecular Biology, Medical Biochemistry and Pathology, CHU de Québec - Université Laval, Quebec City, Québec, Canada.
Norbert DionDepartment of Surgery, Division of Orthopedic Surgery, CHU de Quebec-Universite Laval, Quebec City, Québec, Canada.
Sebastiano LavaPediatric Cardiology Unit, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, Lausanne, Switzerland.
Eric BouffetThe Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.
Nada JabadoDivision of Experimental Medicine, Montreal Children's Hospital, McGill University and McGill University Health Centre, Montreal, Québec, Canada.
Samuele RenziDivision of Hemato-Oncology, CHU de Québec-Université Laval, 2705, Boulevard Laurier, Quebec City, G1V 4G2, QC, Canada. Samuele.Renzi.med@ssss.gouv.qc.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 25-year-old female patient with neurofibromatosis type 1 who was diagnosed with a thalamic high-grade glioma (HGG). She was initially treated with a combination of radiotherapy and concurrent temozolomide (TMZ). Following 7 months of TMZ treatment, an MRI showed tumor progression. Empiric treatment with trametinib was started, which demonstrated significant regression of the lesion. She is currently alive with stable disease 4 years post-initial diagnosis.

Indexed as

Antineoplastic AgentsBrain NeoplasmsGliomaNeurofibromatosis 1PyridonesPyrimidinonesAdultFemaleHumansMagnetic Resonance ImagingTemozolomideAntineoplastic AgentsPyridonesPyrimidinonesTemozolomidetrametinibHGAPHigh-grade glioma (HGG)Neurofibromatosis type 1 (NF1)Targeted therapyTrametinib

Identifiers

PMID40461678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.